Inovio Pharmaceuticals, Inc. (INO)
| Market Cap | 256.89M +144.7% |
| Revenue (ttm) | 298,901 +63.9% |
| Net Income | -71.14M |
| EPS | -0.91 |
| Shares Out | 179.64M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5,218,568 |
| Open | 1.440 |
| Previous Close | 1.460 |
| Day's Range | 1.391 - 1.475 |
| 52-Week Range | 0.563 - 2.720 |
| Beta | 1.73 |
| Analysts | Strong Buy |
| Price Target | 6.33 (+342.87%) |
| Earnings Date | Nov 10, 2026 |
About INO
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses SynCon, to help engineer precisely designed plasmid DNA plasmids, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company’s lead product candidate is INO-3107 for HPV-related recurrent respiratory papillomatosis and i... [Read more]
Financial Performance
In 2025, Inovio Pharmaceuticals's revenue was $65,343, a decrease of -69.99% compared to the previous year's $217,756. Losses were -$84.95 million, -20.80% less than in 2024.
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for INO stock is "Strong Buy." The 12-month stock price target is $6.33, which is an increase of 342.87% from the latest price.
News
Inovio price target lowered to $6 from $8 at Piper Sandler
Piper Sandler lowered the firm’s price target on Inovio (INO) to $6 from $8 and keeps an Overweight rating on the shares. The firm notes the company ended Q3 with…
INOVIO to Participate in Upcoming Investor Conferences
PLYMOUTH MEETING, Pa., Nov. 11, 2026 /PRNewswire/ -- INOVIO (NASDAQ: INO), a commercial-stage biotechnology company focused on developing DNA medicines to help treat and protect people from HPV-relate...
Inovio Pharmaceuticals Earnings Call Transcript: Q3 2026
FDA approval of VOCERYQ opens a commercial launch focused on reducing RRP surgeries. Q3 net loss was $49.2M, including a $26.9M non-cash warrant fair-value loss; financing and cash are projected to fund operations into late Q4 2027, excluding product revenue.
Inovio Pharmaceuticals Quarterly report: Q3 2026
Inovio Pharmaceuticals has published its Q3 2026 quarterly earnings report on November 10, 2026.
Inovio Pharmaceuticals Earnings release: Q3 2026
Inovio Pharmaceuticals released its Q3 2026 earnings on November 10, 2026, summarizing the period's financial results.
Inovio Pharmaceuticals Slides: Q3 2026
Inovio Pharmaceuticals has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 10, 2026.
INOVIO Reports Third Quarter 2026 Financial Results and Recent Business Highlights
VOCERYQ™ (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd) granted accelerated approval by U.S. Food and Drug Administration (FDA) to reduce the frequency of surgery in adults with Recurr...
Inovio price target raised to $8 from $3 at Jefferies
Jefferies raised the firm’s price target on Inovio (INO) to $8 from $3 and keeps a Buy rating on the shares. The firm views VOCERYQ’s accelerated approval as clearly positive,…
INOVIO Announces Pricing of Approximately $75 Million Public Offering
PLYMOUTH MEETING, Pa., Nov. 5, 2026 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protec...
Inovio announces common stock offering, no amount given
Inovio (INO) Pharmaceuticals announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All of the shares in the proposed offering will…
INOVIO Announces Proposed Public Offering of its Common Stock
PLYMOUTH MEETING, Pa., Nov. 5, 2026 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protec...
INOVIO to Report Third Quarter 2026 Financial Results on November 10, 2026
PLYMOUTH MEETING, Pa., Nov. 2, 2026 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-rela...
INOVIO to Participate in Upcoming Scientific Conferences
PLYMOUTH MEETING, Pa., Nov. 2, 2026 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-rela...
Precigen sinks after competitor Inovio wins FDA approval
Shares of Precigen (PGEN) (PCGN) are down 27% to $5.05 in early trading after Inovio’s (INO) competing recurrent respiratory papillomatosis received FDA approval.
Why Is Penny Stock Inovio Pharmaceuticals (INO) Up 243% Today?
Inovio Pharmaceuticals stock experienced a large rally on Monday after an FDA update for its RRP treatment.
Inovio Pharmaceuticals Transcript: FDA announcement
VOCERYQ received FDA Accelerated Approval to reduce surgery frequency in adults with RRP. In the FDA efficacy population, 27% required no surgery in the 12 months after the dosing window; a confirmatory study is planned.
Inovio Pharmaceuticals Press release: FDA announcement
Inovio Pharmaceuticals issued a press release on November 2, 2026, disclosing material business information to investors.
Inovio Pharmaceuticals Slides: FDA announcement
Inovio Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on November 2, 2026.
Why Penny Stock Inovio Pharmaceuticals (INO) Is Skyrocketing Over 200% Today — and How Much Upside Wall Street Sees From Here
For investors who had nearly written off Inovio Pharmaceuticals (NASDAQ:INO) after watching its shares lose 65% of their value this year, Monday morning is delivering quite a surprise. The biotechnolo...
Inovio upgraded to Buy from Neutral at H.C. Wainwright
H.C. Wainwright upgraded Inovio (INO) to Buy from Neutral with a $5 price target after the FDA granted accelerated approval for Voceryq to reduce the frequency of surgery in adults…
Inovio announces FDA accelerated approval of Voceryq
Inovio (INO) announced that the FDA has granted accelerated approval for Voceryq, previously referred to as INO-3107, to reduce the frequency of surgery in adults with RRP. This indication is…
INOVIO Announces FDA Accelerated Approval of VOCERYQ™, an Immunotherapy to Reduce the Frequency of Surgery in Adults with Recurrent Respiratory Papillomatosis (RRP)
INOVIO delivers a new nonsurgical treatment option with a broad indication for adults living with RRP, a rare and debilitating disease that often requires surgery VOCERYQ™ is a plasmid DNA-based immun...
Inovio announces favorable judgment in litigation with VGXI and GeneOne
INOVIO (INO) Pharmaceuticals announced that it secured a judgment in its favor, in the amount of $80,416,101, on all claims it filed against defendants VGXI and GeneOne Life Science in…
INOVIO Announces Favorable Judgment in Litigation with VGXI, Inc. and GeneOne Life Science
PLYMOUTH MEETING, Pa., Oct. 20, 2026 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and prote...
Inovio Pharmaceuticals Transcript: H.C. Wainwright 28th Annual Global Investment Conference
INO-3107 for RRP is nearing FDA approval with strong clinical data showing significant reductions in surgeries and broad patient benefit. Commercial launch preparations are underway, while the pipeline advances through partnerships and promising early-stage programs.